Literature DB >> 11763113

A review of the relationship between patent foramen ovale and type II decompression sickness.

M J Saary1, G W Gray.   

Abstract

The significance of patent foramen ovale (PFO) in the pathophysiology of Type II decompression sickness (DCS) remains controversial. PFOs are common, occurring in approximately one quarter of the normal population, thus making right-to-left shunting of venous gas emboli (VGE) a theoretical concern in both hyper- and hypobaric situations. Despite this high prevalence of PFO in the general population, and the relatively common occurrence of venous gas bubbles in diving and altitude exposures, the incidence of Type II DCS in diving or with altitude is remarkably low. Although the literature supports a relationship between the presence and size of PFO and cryptogenic stroke, and an increased relative risk of Type II DCS with a PFO in divers, the absolute increase in risk accrued is small. Hence, the value of screening is also controversial. This paper presents a summary of the literature on PFOs and DCS in animals, and in human altitude and diving, focusing on the latter; as well the analogous literature on cryptogenic stroke. The results of an examination of the literature on detection of, screening for, and treatment of PFOs is also presented.

Entities:  

Mesh:

Year:  2001        PMID: 11763113

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  3 in total

1.  A 32-year-old man with acute bilateral leg weakness following recreational diving.

Authors:  Dariush Dowlatshahi; Matthew J Hogan; Mukul Sharma; Christopher G Wherrett
Journal:  CMAJ       Date:  2004-06-08       Impact factor: 8.262

Review 2.  High-altitude headache.

Authors:  Michael J Marmura; Pablo Bandres Hernandez
Journal:  Curr Pain Headache Rep       Date:  2015-05

Review 3.  Evaluation and management of decompression illness--an intensivist's perspective.

Authors:  Kay Tetzlaff; Erik S Shank; Claus M Muth
Journal:  Intensive Care Med       Date:  2003-11-05       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.